MedTrace Logo

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

NCT05193721 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-03-20

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

SHR-1901

SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2024-06-30
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193721 on ClinicalTrials.gov